XNYS · Healthcare · Medical Care Facilities
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | 2.35 | 2.87 | +22.13% | $3.42B | ✅ Beat | +4.43% | +27.70% | — |
| 2026-02-02 | Q4 2025 | 3.21 | 3.40 | +5.92% | $3.62B | ✅ Beat | +14.50% | +23.79% | +39.21% |
| 2025-10-29 |
| Q3 2025 |
| 3.22 |
| 2.51 |
| -22.05% |
| $3.42B |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | 2.73 | 2.95 | +8.06% | $3.38B | ✅ Beat | — | — | — |
| 2025-02-13 | Q4 2024 | 2.14 | 2.24 | +4.67% | $3.29B | ✅ Beat | -11.09% | -17.59% | -15.71% |
| 2024-10-29 | Q3 2024 | 2.73 | 2.59 | -5.13% | $3.26B | ❌ Miss | -10.80% | -7.09% | +4.96% |
| 2024-08-06 | Q2 2024 | 2.54 | 2.59 | +1.97% | $3.19B | ✅ Beat | -2.20% | +6.46% | +8.58% |
| 2024-05-02 | Q1 2024 | 1.95 | 2.38 | +22.05% | $3.07B | ✅ Beat | -5.48% | -3.02% | +2.37% |
Showing last 8 quarters.